JP7692218B2 - ターゲティングされた肺送達組成物およびそれを使用する方法 - Google Patents

ターゲティングされた肺送達組成物およびそれを使用する方法 Download PDF

Info

Publication number
JP7692218B2
JP7692218B2 JP2022520386A JP2022520386A JP7692218B2 JP 7692218 B2 JP7692218 B2 JP 7692218B2 JP 2022520386 A JP2022520386 A JP 2022520386A JP 2022520386 A JP2022520386 A JP 2022520386A JP 7692218 B2 JP7692218 B2 JP 7692218B2
Authority
JP
Japan
Prior art keywords
phage
particles
peptide
amino acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550452A (ja
JP2022550452A5 (https=
JPWO2021067571A5 (https=
Inventor
レナタ パスカリーニ
ワディー アラップ
ダニエラ スタキチーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of JP2022550452A publication Critical patent/JP2022550452A/ja
Publication of JP2022550452A5 publication Critical patent/JP2022550452A5/ja
Publication of JPWO2021067571A5 publication Critical patent/JPWO2021067571A5/ja
Application granted granted Critical
Publication of JP7692218B2 publication Critical patent/JP7692218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022520386A 2019-10-04 2020-10-01 ターゲティングされた肺送達組成物およびそれを使用する方法 Active JP7692218B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910998P 2019-10-04 2019-10-04
US62/910,998 2019-10-04
PCT/US2020/053758 WO2021067571A1 (en) 2019-10-04 2020-10-01 Targeted pulmonary delivery compositions and methods using same

Publications (4)

Publication Number Publication Date
JP2022550452A JP2022550452A (ja) 2022-12-01
JP2022550452A5 JP2022550452A5 (https=) 2023-10-05
JPWO2021067571A5 JPWO2021067571A5 (https=) 2023-10-05
JP7692218B2 true JP7692218B2 (ja) 2025-06-13

Family

ID=75337530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520386A Active JP7692218B2 (ja) 2019-10-04 2020-10-01 ターゲティングされた肺送達組成物およびそれを使用する方法

Country Status (6)

Country Link
US (1) US20220332759A1 (https=)
EP (1) EP4041276A4 (https=)
JP (1) JP7692218B2 (https=)
AU (1) AU2020357866A1 (https=)
CA (1) CA3153476A1 (https=)
WO (1) WO2021067571A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241203A1 (en) * 2020-07-06 2023-08-03 Rutgers, The State University Of New Jersey Enhancing immune responses through targeted antigen expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US7659252B2 (en) * 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Accession No.A0A4R6BLG7，Detabase UniProtKB［online］，2019年07月31日，［2024年8月21日検索］,URL,https://www.uniprot.org/uniprotkb/A0A4R6BLG7/entry
Christopher J. Morris et al.，Journal of Controlled Release，2010年12月20日，Vol.151, No.1，p.83-94

Also Published As

Publication number Publication date
AU2020357866A1 (en) 2022-04-21
JP2022550452A (ja) 2022-12-01
EP4041276A4 (en) 2024-02-07
WO2021067571A1 (en) 2021-04-08
CA3153476A1 (en) 2021-04-08
US20220332759A1 (en) 2022-10-20
EP4041276A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
TWI297040B (en) Recombinant baculovirus and virus-like particle
EP2480672B1 (fr) Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
JP2016536346A (ja) 免疫原性の中東呼吸器症候群コロナウイルス（ＭＥＲＳ−ＣｏＶ）組成物および方法
US12297233B2 (en) FcRn-targeted mucosal vaccination against influenza infections
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2010540674A (ja) Ｈｉｖ特異抗体に基づくｈｉｖ予防ワクチン
CN118119930A (zh) 抗新型冠状病毒感染的mRNA疫苗的组合物和方法
US20230241203A1 (en) Enhancing immune responses through targeted antigen expression
BE1022174B1 (fr) Vaccin
JP7692218B2 (ja) ターゲティングされた肺送達組成物およびそれを使用する方法
WO2025092866A1 (zh) 一种多价流感mRNA疫苗
WO2025189435A1 (zh) 针对猫fipv的多表位抗原构建rna疫苗的方法
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
WO2023069971A2 (en) Cd24-loaded vesicles for treatment of cytokine storm and other conditions
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
EP4541806A1 (en) Modified coronavirus spike antigen protein and uses thereof
CN116444629B (zh) 一种中东呼吸综合征冠状病毒的重组蛋白及疫苗
RU2852174C1 (ru) Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения
US20230140025A1 (en) Vectors for Producing Virus-Like Particles and Uses Thereof
US9556236B1 (en) Compositions and methods for treating respiratory syncytial virus infection
US20260097115A1 (en) Immunogenic compositions and use thereof
Ogriņa Molecular Solutions for Plant Virus-Like Particles Based Vaccine Generation
US20100172925A1 (en) Hla-a2-restricted t-cell epitopes of the respiratory syncytial virus fusion protein as peptide-based vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250527

R150 Certificate of patent or registration of utility model

Ref document number: 7692218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150